Molecular Formula | C16H26GdN5O8.H2O |
Molar Mass | 591.673 |
Solubility | DMSO: 16 mg/mL |
Storage Condition | Inert atmosphere,Store in freezer, under -20°C |
In vivo study | The half-lives of Gadodiamide in rats, rabbits, and monkeys were 18,38, and 75 minutes, respectively. Gadodiamide is rapidly excreted mainly through the kidneys. Gadodiamide administered intravenously at 0.3 mmol/kg was stable in vivo, and 99% of the Gadodiamide was excreted in urine. Gadodiamide produces generalized myoclonus for more than a few hours. Gadodiamide itself produces lesions in the central cerebellar area, similar to gadodiamide, but not others. Gadodiamide spreads rapidly within 2 min from the lateral ventricle injection throughout the fourth ventricle of the uncinate vertebrae and the margendi and intervertebral foramen ventricular system. In anesthetized dogs, Gadodiamide caused transient, but statistically significant reductions in aortic pressure, left ventricular pressure, left ventricular contraction and relaxation, and systemic and pulmonary vascular resistance indices, and increased blood flow to the aorta. Gadodiamide injections produced less severe hemodynamic changes than gadopentetate dimeglumine. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.69 ml | 8.451 ml | 16.901 ml |
5 mM | 0.338 ml | 1.69 ml | 3.38 ml |
10 mM | 0.169 ml | 0.845 ml | 1.69 ml |
5 mM | 0.034 ml | 0.169 ml | 0.338 ml |